Health

In a recent piece in Forbes, former president of Pfizer research and development John LaMattina discusses the limitations of the popular antidepressants classified as selective serotonin reuptake inhibitors, or SSRIs.

LaMattina mentions an antidepressant that pharmaceutical company Lundbeck is developing, called Lu AA21004. He writes that researchers are hoping the new medication won’t have some of the drawbacks of SSRIs, which include Prozac and Zoloft.

Those drawbacks, according to LaMattina, include a ...

An article in The Vancouver Sun examines the controversy surrounding the use of antidepressants by pregnant women.

The report quotes the director of a Canadian program that provides information and research about medical hazards for pregnant women as saying that quitting medication can be risky for clinically depressed patients who are pregnant. That can lead to hospitalization, suicide attempts, postpartum depression and the inability to care for oneself.

But the report also ...

A study by Beth Israel Deaconess Medical Center in Boston and the Massachusetts Institute of Technology in Cambridge finds that critically ill patients were more likely to die if they were taking commonly prescribed antidepressants before being admitted to the intensive care unit.

Specifically, the research examined the class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs).

According to a report on the study ...

A report from station KAIT out of Arkansas explores the question of whether antidepressants cause suicidal thoughts in children.

According to the report, the assertion that there’s a link between antidepressant use and suicidal thoughts in children is controversial. But it said some studies have suggested such a link exists.

A number of studies have indicated that antidepressants categorized as selective serotonin reuptake inhibitors, widely hailed as wonder drugs in the 1990s, ...